Rociletinib (CO-1686) enhanced the efficacy of chemotherapeutic agents in ABCG2-overexpressing cancer cells in vitro and in vivo

• Egile Nagusiak: Fanpu Zeng (Egilea), Fang Wang (Egilea), Zongheng Zheng (Egilea), Zhen Chen (Egilea), Kenneth Kin Wah To (Egilea), Hong Zhang (Egilea), Qian Han (Egilea), Liwu Fu (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2020-05-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Overexpression of adenosine triphosphate (ATP)-binding cassette subfamily G member 2 (ABCG2) in cancer cells is known to cause multidrug resistance (MDR), which severely limits the clinical efficacy of chemotherapy. Currently, there is no FDA-approved MDR modulator for clinical use. In this study, r...